Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Sana Biotechnology published a follow-on study in NEJM showing 14-month durability of its hypoimmune-modified islet cell therapy for type 1 diabetes without immunosuppression.
Immutep's INSIGHT-003 trial showed a median overall survival (mOS) of 30.9 months in first-line non-squamous NSCLC patients, outperforming historical benchmarks.
Neuberger Berman launched the Neuberger Quality Select ETF (NQLT) on July 13, 2026, an actively managed fund focused on mid- and large-cap quality companies.
